Previous studies have shown low TMB levels, HLA loss, low CD8 infiltration, low LAG-3 or low TIM-3 expression to be associated with lower chance of response [12, 40, 43, 46], but when addressing our intrapatient analyses of regressive versus progressive tumor lesions, these parameters did not validate. This evidence concerns the gene HAVCR2 and neoplasm.